Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bristol-Myers Squibb to receive fast-track NICE appraisal for Eliquis

Bristol-Myers Squibb to receive fast-track NICE appraisal for Eliquis

24th January 2013

Bristol-Myers Squibb and partner Pfizer have been granted a fast-tracked recommendation for their oral anticoagulant Eliquis from the UK's National Institute for Health and Clinical Excellence.

The regulator has issued a final appraisal determination endorsing the apixaban-based therapy for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation with one or more risk factors.

It was concluded that Eliquis represents a cost-effective and more clinically efficacious option than warfarin, while also resulting in fewer bleeding incidents.

Atrial fibrillation is the most common heart rhythm disorder in the UK and there are a number of drawbacks associated with warfarin therapy, making this new approval an important development.

Amadou Diarra, UK and Ireland vice-president for Bristol-Myers Squibb, said: "We look forward to working with the NHS and other partners to ensure that, where clinically appropriate, patients are provided with rapid access to apixaban."

This comes after the drug was also approved by the US Food and Drug Administration last month.ADNFCR-8000103-ID-801527808-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.